Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 4442 results
GSK, Regeneron to mine gene data from 500000 volunteer participants in UK
Regeneron Pharmaceuticals announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource.
Drug Research > Drug Discovery & Development > News
Pierre Fabre, H-Immune partner on immuno-oncology therapeutics
French pharma Pierre Fabre has entered into a strategic research partnership with H-Immune to develop immuno-oncology therapeutics using the latter’s technology platform to generate lead candidates of fully human antibodies.
Drug Research > Drug Discovery & Development > News
X-Chem, Ono to collaborate on multi-target drug discovery
X-Chem, a biotechnology firm focused on developing novel small molecule therapeutics by applying its innovative drug discovery platform, has entered into a partnership with Ono Pharmaceutical.
Drug Research > Drug Discovery & Development > News
SalvaRx to invest in Rift Biotherapeutics
SalvaRx, a subsidiary of SalvaRx Group, has agreed to invest in Delaware-based biotechnology company Rift Biotherapeutics which focuses on the development of antibodies for use in oncology.
Drug Research > Drug Discovery & Development > News
Circassia signs deal for US rights to two AstraZeneca COPD drugs
By PBR Staff Writer
UK-based Circassia Pharmaceuticals has agreed to pay up to $230m for certain US commercial rights for Tudorza and Duaklir, two drugs developed by AstraZeneca to treat chronic obstructive pulmonary disease (COPD).
Drug Research > Drug Discovery & Development > News
Cell Medica raises £60m to advance multiple cancer programmes
Cellular immunotherapy company, Cell Medica has secured £60m in a Series C financing round with participation from existing investors Touchstone Innovations, funds managed by Woodford Investment Management, and funds managed by Invesco Perpetual.
Drug Research > Drug Discovery & Development > News
Scientists link noncoding genetic variants to neurodevelopmental disorders
Scientists from the Max Planck Institute for Psycholinguistics and Radboud University in Nijmegen found that genetic variation in the non-coding DNA may lead to language impairments in children and other neurodevelopmental disorders such as schizophrenia, autism, and bipolar disorder.
Drug Research > Drug Discovery & Development > News
CRISPR Therapeutics licenses cell engineering platform from MaxCyte
CRISPR Therapeutics and Casebia Therapeutics, its joint venture with Bayer, have signed a licensing agreement for a cell transfection platform from MaxCyte.
Drug Research > Drug Discovery & Development > News
Daiichi Sankyo enters into drug discovery and licensing deal with Heptares
Daiichi Sankyo has signed an agreement with Heptares Therapeutics to discover and develop small-molecules for the treatment of pain.
Drug Research > Drug Discovery & Development > News
Scientists use kiss of death to neutralize disease-causing proteins
By PBR Staff Writer
Scientists at the University of Dundee in Scotland have discovered how to destroy undruggable cancer proteins that lead to several strains of the disease.
Drug Research > Drug Discovery & Development > News
Google’s venture arm leads $51.7m investment in Spero Therapeutics
Spero Therapeutics, a biopharmaceutical firm engaged in the development of novel therapies to treat bacterial infections, has completed a $51.7m Series C preferred financing led by new investor GV (formerly Google Ventures).
Drug Research > Drug Discovery & Development > News
Heat Biologics to acquire controlling stake in Pelican Therapeutics
Heat Biologics has agreed to buy an 80% controlling stake in Pelican Therapeutics, a privately held immuno-oncology company engaged in the development of agonists to TNFRSF25, a differentiated T cell costimulatory receptor.
Drug Research > Drug Discovery & Development > News
Bioversys, Aptuit partner to find novel antibiotic targets
Bioversys and Aptuit have commenced their joint collaboration to identify and validate novel targets and molecules for Gram-negative bacteria.
Drug Research > Drug Discovery & Development > News
Vertex to buy cystic fibrosis drug from Concert Pharmaceuticals
Vertex Pharmaceuticals has agreed to acquire CTP-656 from Concert Pharmaceuticals to treat cystic fibrosis.
Drug Research > Drug Discovery & Development > News
FDA accepts Advaxis' IND for personalized neoepitope immunotherapy ADXS-NEO
The US Food and Drug Administration (FDA) has accepted Advaxis’ Investigational New Drug (IND) application for ADXS-NEO, a personalized neoantigen-targeted approach to cancer immunotherapy that is being developed in partnership with Amgen.
Drug Research > Drug Discovery & Development > News
61-75 of 4442 results